1. ATwo-Centre Audit on Changes in Ejection Fraction (EF) following sequential anthracycline chemotherapy and Trastuzumab (T) in patients with HER2+ Early Breast Cancer (EBC). (March 2017) Authors: Fernando, S.; Conway, A.; Mitchell, H.; Sandri, I.; Wardley, A.; Okonta, L.; Mansi, J. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Changes in Ejection Fraction (EF) Following Sequential Anthracycline and Trastuzumab in Patients with HER2+ Early Breast Cancer (EBC) – Is There a Need for Two Echocardiograms Pre-trastuzumab?. Issue 6 (June 2017) Authors: Fernando, S.; Okonta, L.; Sandri, I.; Wardley, A.; Mitchell, H.; Conway, A.M. Journal: Clinical oncology Issue: Volume 29:Issue 6(2017) Page Start: e99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pretreatment DPYD Genotyping Reduces the Risk of Capecitabine-associated Severe Toxicities: a Prospective Validation Study. Issue 7 (July 2019) Authors: Stavraka, C.; Pouptsis, A.; Okonta, L.; De Souza, K.; Marinaki, A.; Karapanagiotou, E.; Papadatos-Pastos, D.; Mansi, J. Journal: Clinical oncology Issue: Volume 31:Issue 7(2019) Page Start: e114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗